Table 3 Summary of the results for grade 3 or greater adverse events
From: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma
Outcomes | Number of cohorts | RR and 95%CI | P value | Heterogeneity (%) | P value for heterogeneity |
|---|---|---|---|---|---|
Fever | 3 | 0.83 (0.50–1.38) | 0.470 | 8.6 | 0.335 |
Infection | 9 | 1.14 (0.91–1.43) | 0.267 | 62.9 | 0.006 |
Mucositis | 4 | 1.15 (0.67–1.98) | 0.615 | 48.6 | 0.120 |
Liver toxicity | 3 | 0.63 (0.26–1.52) | 0.307 | 0.0 | 0.481 |
Cardiac toxicity | 8 | 1.31 (0.87–1.98) | 0.197 | 18.0 | 0.288 |
Neurologic toxicity | 9 | 0.88 (0.66–1.18) | 0.393 | 0.0 | 0.572 |
Renal toxicity | 3 | 0.36 (0.10–1.38) | 0.136 | 0.0 | 0.773 |
Lung toxicity | 7 | 1.16 (0.73–1.85) | 0.539 | 33.8 | 0.170 |
Nausea or vomiting | 7 | 0.75 (0.47–1.20) | 0.232 | 0.0 | 0.481 |
Constipation | 2 | 0.61 (0.12–3.20) | 0.560 | 27.8 | 0.239 |
Diarrhea | 4 | 2.63 (1.18–5.86) | 0.019 | 0.0 | 0.569 |
Neutropenia | 8 | 1.04 (0.95–1.14) | 0.363 | 26.0 | 0.222 |
Anemia | 11 | 1.18 (0.97–1.44) | 0.096 | 21.4 | 0.239 |
Thrombocytopenia | 11 | 1.48 (1.08–2.02) | 0.015 | 54.9 | 0.014 |
Leucocytopenia | 6 | 1.06 (0.94–1.20) | 0.342 | 0.0 | 0.971 |
Granulocytopenia | 2 | 1.16 (0.71–1.88) | 0.549 | 23.7 | 0.252 |